Advances in cancer treatment have greatly improved survival rates of children with cancer. However, these same chemotherapeutic or radiologic treatments may result in long-term health consequences.

SGLT2 inhibitors may worsen heart failure outcomes from chemotherapy, highlighting the need for further long-term studies on ...

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human ...

Compared with White patients, Black and Hispanic patients who receive anthracycline chemotherapy for treatment of cancer are at increased risk for cardiotoxicity. Black and Hispanic patients who ...

Trastuzumab-mediated cardiotoxicity was originally described in women with metastatic breast cancer. The incidence rates were 13% when the antibody was administered in combination with paclitaxel and ...

In patients with gastrointestinal cancers treated with fluoropyrimidine-based chemotherapy agents, better overall survival at 1 year offsets a small increase in their risk of CV events, new data ...

Heart disease is the leading cause of death among Americans. Recently the bio-tech industry has been exploding with cardiac research like last week's heart attack preventing nanobots. New research by ...

Please provide your email address to receive an email when new articles are posted on . A miniature, three-dimensional heart model, called the “heart-on-a-chip,” successfully used reprogrammed stem ...

New research suggests that a healthy microbiome before chemotherapy could help protect breast cancer patients against heart damage, or cardiotoxicity, as a result of cancer therapy. Researchers found ...

Future Cardiol. 2012;8(4):647-670. Although redox-induced damage is likely involved in anthracycline-induced cardiotoxicity, some evidence suggests that it is not the only mechanism at play. Several ...